|
US4690915A
(en)
|
1985-08-08 |
1987-09-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adoptive immunotherapy as a treatment modality in humans
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
US5350674A
(en)
|
1992-09-04 |
1994-09-27 |
Becton, Dickinson And Company |
Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
HK1047109A1
(zh)
|
1999-10-15 |
2003-02-07 |
University Of Massachusetts |
作为指定基因干预工具的rna干预轨迹基因
|
|
US6326193B1
(en)
|
1999-11-05 |
2001-12-04 |
Cambria Biosciences, Llc |
Insect control agent
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
KR20030032922A
(ko)
|
2000-02-24 |
2003-04-26 |
싸이트 테라피스 인코포레이티드 |
세포의 동시 자극 및 농축
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
AU2001275474A1
(en)
|
2000-06-12 |
2001-12-24 |
Akkadix Corporation |
Materials and methods for the control of nematodes
|
|
US7745140B2
(en)
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
|
US20030170238A1
(en)
|
2002-03-07 |
2003-09-11 |
Gruenberg Micheal L. |
Re-activated T-cells for adoptive immunotherapy
|
|
CA2559955C
(en)
|
2004-03-15 |
2016-02-16 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded rna
|
|
WO2005118788A2
(en)
|
2004-05-27 |
2005-12-15 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses therefor
|
|
CA3285826A1
(en)
|
2012-02-22 |
2026-03-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
|
|
AU2013266968B2
(en)
|
2012-05-25 |
2017-06-29 |
Emmanuelle CHARPENTIER |
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
EP2840140B2
(en)
|
2012-12-12 |
2023-02-22 |
The Broad Institute, Inc. |
Crispr-Cas based method for mutation of prokaryotic cells
|
|
CN113355357B
(zh)
|
2012-12-12 |
2024-12-03 |
布罗德研究所有限公司 |
对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
|
|
IL311390A
(en)
|
2013-03-15 |
2024-05-01 |
Memorial Sloan Kettering Cancer Center |
Preparations and methods for immunotherapy
|
|
MX373687B
(es)
|
2013-11-21 |
2020-07-07 |
Ucl Business Ltd |
Célula natural (nk)
|
|
AU2017286835B2
(en)
|
2016-06-29 |
2023-12-14 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing
|
|
EP3263595A1
(en)
|
2016-06-30 |
2018-01-03 |
Medizinische Hochschule Hannover |
Fusion protein for use in the treatment of hvg disease
|
|
SG11202002520UA
(en)
*
|
2017-09-19 |
2020-04-29 |
Univ British Columbia |
Anti-hla-a2 antibodies and methods of using the same
|
|
WO2019068007A1
(en)
*
|
2017-09-28 |
2019-04-04 |
Immpact-Bio Ltd. |
UNIVERSAL PLATFORM FOR PREPARING AN INHIBITORY CHIMERIC ANTIGEN RECEPTOR (ICAR)
|
|
CN110484507B
(zh)
*
|
2018-01-31 |
2023-10-13 |
温州医科大学 |
一种靶向肿瘤Her2的新型嵌合抗原受体T细胞的制备技术
|
|
CN112567025B
(zh)
*
|
2018-08-10 |
2025-01-17 |
国立大学法人京都大学 |
Cd3阳性细胞的制造方法
|
|
BR112021006100A2
(pt)
*
|
2018-09-28 |
2021-07-20 |
Immpact-Bio Ltd. |
métodos para identificação de pares de receptor de antígeno ativador (acar)/receptor de antígeno quimérico inibitório (icar) para uso em terapias de câncer
|
|
KR102691932B1
(ko)
*
|
2019-04-03 |
2024-08-06 |
프리시젼 바이오사이언시스 인코포레이티드 |
마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포
|
|
WO2021030153A2
(en)
|
2019-08-09 |
2021-02-18 |
A2 Biotherapeutics, Inc. |
Engineered t cell receptors and uses thereof
|
|
MX2022001711A
(es)
*
|
2019-08-09 |
2022-05-10 |
A2 Biotherapeutics Inc |
Receptores en la superficie celular que responden a la perdida de heterocigosidad.
|
|
JP2022546315A
(ja)
|
2019-08-20 |
2022-11-04 |
センティ バイオサイエンシズ インコーポレイテッド |
キメラ抑制性受容体
|
|
EP4058561A1
(en)
|
2019-11-12 |
2022-09-21 |
A2 Biotherapeutics, Inc. |
Engineered t cell receptors and uses thereof
|
|
CN115052887B
(zh)
|
2019-12-11 |
2026-03-31 |
A2生物治疗公司 |
基于lilrb1的嵌合抗原受体
|
|
WO2021222576A1
(en)
|
2020-05-01 |
2021-11-04 |
A2 Biotherapeutics, Inc. |
Pag1 fusion proteins and methods of making and using same
|
|
JP2023540339A
(ja)
*
|
2020-09-04 |
2023-09-22 |
インパクト バイオ ユーエスエー インコーポレイテッド |
癌治療に使用するためのバイシストロン性阻害性キメラ抗原受容体（ｉＣＡＲ）／活性化キメラ抗原受容体（ａＣＡＲ）構築物
|
|
AU2021386366A1
(en)
*
|
2020-11-24 |
2023-06-29 |
A2 Biotherapeutics, Inc. |
Adoptive cell therapy for treatment of cancer associated with loss of heterozygosity
|
|
WO2023274385A1
(zh)
*
|
2021-07-01 |
2023-01-05 |
宁波茂行生物医药科技有限公司 |
靶向her2的通用型car-t细胞及其制备方法
|